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This study evaluated whether the VEGF mRNA level in oral squamous cell carcinoma (OSCC) tis-
sue could be a biomarker to predict the progression and prognosis of OSCCs in Taiwan.
Methods: This study used quantitative real-time reverse transcription-polymerase chain reac-
tion (quantitative RT-PCR) to detect the VEGF mRNA levels in 60 OSCC specimens. Threshold cy-
cle (CT) was defined as the PCR cycle number needed to generate a predetermined amount of
DNA (threshold). The relative amount of tissue VEGF mRNA, standardized against the amount
of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA, was expressed as DCTZ (VEGF
CT e GAPDH CT). For a chosen threshold, a smaller starting copy number of mRNA results in a
higher CT value. Thus, the lower the DCT, the greater the copy number of VEGF mRNA in tissues.
Results: The lower mean VEGF mRNA DCT value was significantly associated with OSCCs with
larger tumor size (pZ 0.040), positive lymph node metastasis (pZ 0.023), and more advanced
clinical stages (pZ 0.008). VEGF mRNA DCT value< 4.2 (pZ 0.026) was identified as an inde-
pendent unfavorable prognosis factor using multivariate regression analyses. Moreover, Kaplan
eMeier curve showed that OSCC patients with a VEGF mRNA DCT value< 4.2 had a significantly
poorer overall survival than those with a VEGFmRNADCT value4.2 (log-rank test, pZ 0.0427).ave no conflicts of interest relevant to this article.
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Oral squamous cell carcinoma (OSCC) is the most frequent
malignancy of the oral cavity and late-stage OSCCs with
neck metastasis often associated with poor prognosis of
patients.1 In Taiwan, the mortality rate of head and neck
cancers is in fifth place in the overall population and the
fourth place in male populations in 2011.2
OSCC is an aggressive epithelial neoplasm. Despite the
advances in early detection and treatment of OSCC in
recent years,3 the overall survival rate of OSCC is still not
promising, probably due to the lack of a good marker for
early diagnosis and prediction of the progression and
prognosis of OSCC. Vascular endothelial growth factor
(VEGF) can promote angiogenesis which is essential for
cancer growth and metastasis.4e6 Therefore, VEGF protein
or mRNA may be a good marker for prediction of cancer
progression and prognosis.
VEGF can increase vascular permeability, promote endo-
thelial cell proliferation and migration, and inhibit endo-
thelial cell apoptosis.5,6 In humans, the gene encoding VEGF
is located on the short arm of chromosome 6 (6p21.3).7 VEGF
is a mitogen for vascular endothelial cells and helps the
migration and organization of vascular endothelial cells for
neovascularization and tumor micrometastasis.8,9 Over-
expression of VEGFmRNAorprotein has beenassociatedwith
aggressive progression and poor prognosis in several human
cancers, including colorectal,10e12 gastric,13e15 pancre-
atic,16,17 and breast carcinomas18e20 as well as melanoma.21
VEGF is also found to be an important angiogenic cyto-
kine for neovascularization in head and neck cancers.22e29
Overexpression of VEGF mRNA or protein has been re-
ported to be significantly related to poor prognosis and
shorter survival22e27 as well as positive lymph node
metastasis23,28,29 in head and neck cancer patients. In this
study, we evaluated whether the VEGF mRNA level of OSCC
surgical specimens could be a crucial biomarker to predict
the progression, recurrence, and prognosis of OSCCs.
Methods and materials
Patients and oral cancer specimens
Sixty OSCC patients (55 men and 5 women; mean age
56 years; range, 36e81 years) were included in this study.
This study has been reviewed and approved by the Insti-
tutional Review Board of the National Taiwan University
Hospital, Taipei, Taiwan. For each patient and each normal
control patient, an informed consent was obtained before
collection of surgical samples. Surgical samples of OSCCwere collected from 60 OSCC patients. Moreover, 38 biopsy
specimens of normal oral mucosa (NOM) were obtained
from 38 controls (30 men and 8 women; mean age 33 years;
range, 17e55 years) with no oral habits or any oral mucosal
diseases during extraction of an impacted permanent lower
third molar and these were used as the normal controls. All
sample tissues were freshly embedded in optimum cutting
temperature compound (Fisher Scientific, Hanover Park, IL,
USA), snap frozen, and kept at 80C until use. VEGF mRNA
levels in both OSCC and NOM tissues were measured by
quantitative real-time reverse transcription-polymerase
chain reaction (quantitative RT-PCR). OSCC was diagnosed
with histological examination of hematoxylin and eosin-
stained tissue sections.
All OSCC patients underwent total surgical excision of
their tumors plus either selective or radical neck dissection
based on clinically nodal metastasis at the Department of
Oral and Maxillofacial Surgery, National Taiwan University
Hospital during the period from January 2002 to December
2009. Follow-up duration was defined as the period be-
tween the operation date and day of the last visit, ac-
cording to the patient’s chart. If involved surgical margin,
perineural invasion, or lymphovascular permeation of
OSCC, or extracapsular spread of metastatic cervical lymph
node were detected histologically, concurrent post-
operative chemoradiation therapies were also included in
the treatment protocol. In this study, 17 patients under-
went postoperative chemoradiation therapies due to the
presence of aforementioned risk factors of recurrences.
However, none of our patients had received any form of
tumor-specific therapy or induction chemotherapy before
total surgical excision of the lesion. Moreover, there were
33 (55.0%) patients with local recurrences or regional neck
metastases and four (6.7%) patients with distant lung me-
tastases. Salvage treatments for patients with local
regional recurrences were excision of recurrent local can-
cers and neck dissection and those for patients with distant
lung metastases were palliative chemotherapy. Of the 60
OSCC cases, 22 were buccal mucosa cancers, 17 tongue
cancers, and 21 gingiva cancers, palate cancers, or floor of
the mouth cancers. Histological features of OSCC were
further classified into three different types (well-, moder-
ately-, and poorly-differentiated OSCC). Of the 60 OSCC
cases, there were 51 well-differentiated and nine
moderately-differentiated OSCCs. Clinical staging and TNM
status of OSCCs at initial presentation of the tumor were
determined using clinical palpation, head-and-neck mag-
netic resonance imaging, chest X-ray, abdominal sonogra-
phy, and whole body bone scan according to the guidelines
from the American Joint Committee on Cancer (6th
edition).30
VEGF mRNA in oral cancer tissues 607Patients’ oral habits
Details of patients’ oral habits, including daily/weekly
consumption of areca quid, cigarette, and alcohol, as well
as the duration of these habits were recorded. OSCC pa-
tients were defined as areca quid chewers when they
chewed two or more areca quids daily for at least 1 year, as
cigarette smokers when they smoked every day for at least
1 year and consumed >50 packs of cigarettes per year, and
as alcohol drinkers when they drank >4 days and consumed
more than 20 g of pure alcohol per week for at least 1 year.
According to these definitions, 49 (82%) patients were areca
quid chewers, 48 (80%) patients were smokers, and 36 (60%)
patients were drinkers. Furthermore, all of our OSCC pa-
tients stopped chewing areca quids after surgery, some of
them stopped smoking completely after surgery, and some
of them continued to smoke with a reduced number of
cigarettes (<5 cigarettes per day) after surgery according
to the inquisition from the patients and their family
members.Table 1 The mean vascular endothelial growth factor
(VEGF) mRNA DCT value in 60 oral squamous cell carcinoma
(OSCC) samples and 38 normal oral mucosa (NOM) samples.
Groups Mean VEGF mRNA DCT
value  SD
p
NOM (n Z 38) 6.2  2.1 < 0.0001*
OSCC (n Z 60) 4.2  2.4
* A significant difference in the mean VEGF mRNA DCT value
was found between NOM and OSCC samples using Student t test
with p < 0.0001.Quantitative real-time RT-PCR
Total cellular RNA was isolated using an RNA extraction kit
(Qiagen Inc., Alameda, CA, USA) from tissue homogenized
with Trizol reagent (Invitrogen Inc., Carlsbad, CA, USA) as
recommended by the manufacturers. The mRNA expression
levels after each treatment were determined by quantita-
tive RT-PCR using the TaqMan Gene Expression Assays
(Applied Biosystem, Foster City, CA, USA) for VEGF-A (ID:
Hs00900055_m1) and glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH; ID: Hs99999905_m1) on an ABI Prism
real-time PCR system (Applied Biosystem) as previously
described.10 Threshold cycle (CT) is the fractional cycle
number at which the fluorescence generated by cleavage of
the probe exceeds a fixed level above baseline. For a
chosen threshold, a smaller starting copy number results in
a higher CT value. In this study, we chose GAPDH mRNA as
an internal control. The relative amount of tissue VEGF
mRNA, standardized against the amount of GAPDH mRNA,
was expressed as DCT Z (VEGF CT e GAPDH CT).Figure 1 The vascular endothelial growth factor (VEGF)
mRNA expression levels in the oral squamous cell carcinoma
(OSCC) group and the normal oral mucosa (NOM) group. It was
found that the mean VEGF mRNA expression level of the OSCC
group was 4-fold higher than that of the NOM group
(p < 0.0001).Statistical analysis
The mean VEGF mRNA levels between OSCC and NOM
samples and the correlation between the VEGF mRNA levels
in OSCC samples and clinicopathological parameters of
OSCC patients were analyzed using Student t test. Cumu-
lative survival was analyzed with the KaplaneMeier
product-limit method. The duration of overall survival was
measured from the beginning of surgery to the time of
death (complete) or the last follow-up (censored). Com-
parison of cumulative survival between groups was per-
formed using the log-rank test with the Statistica program
7.0 (StatSoft Inc., Tulsa, OK, USA). Univariate and multi-
variate survival analyses were performed with the Cox
proportional hazard regression model to assess additional
prognostic values of the different variables using SPSS
version 22.0. (IBM SPSS, Armonk, NY: IBM Corp.). A p value
<0.05 was considered statistically significant.Results
VEGF mRNA levels in oral cancer tissues
The mean VEGF mRNA levels in 60 OSCC samples and 38
NOM samples are presented in Table 1. The lower DCT value
is interpreted as having higher initial copy numbers of VEGF
mRNA in tissues. We found that the mean VEGF mRNA DCT
value was significantly lower in 60 OSCC samples (4.2  2.4)
than in 38 NOM samples (6.2  2.1, p < 0.0001, Table 1).
Furthermore, the mean VEGF mRNA expression level of the
OSCC group was 4-fold higher than that of the NOM group
(p < 0.0001, Figure 1).Correlation between the VEGF mRNA levels in OSCC
samples and clinicopathological parameters of
OSCC patients
In this study, the lower the DCT, the greater the copy
number of VEGF mRNA in tissues. Correlation between the
mean VEGF mRNA DCT value in 60 OSCC samples and
Table 2 Correlation between the mean vascular endo-
thelial growth factor (VEGF) mRNA DCT values in OSCC
samples and clinicopathological parameters of 60 OSCC
patients.
Parameter Mean VEGF mRNA
DCT value  SD
p
Patients’ age (y)
50 (n Z 21) 3.7  2.0 0.238
>50 (n Z 39) 4.5  2.6
Patients’ sex
Men (n Z 55) 4.1  2.4 0.578
Women (n Z 5) 5.0  3.1
Cancer location
Buccal mucosa (n Z 22) 4.8  1.9 0.220
Tongue (n Z 17) 4.3  3.0
Other oral mucosal sites
(n Z 21)
3.5  2.4
T status
T1 (n Z 20) 5.1  2.5 0.040
T2 (n Z 13) 4.5  2.1
T3 (n Z 11) 4.1  2.2
T4 (n Z 16) 2.9  2.0
N status
N0 (n Z 44) 4.6  2.4 0.023
N1 (n Z 5) 3.5  2.0
N2 (n Z 11) 2.5  1.6
N3 (n Z 0) 0  0
Clinical staging
Stage 1 þ 2 (n Z 29) 5.1  2.5 0.008
Stage 3 þ 4 (n Z 31) 3.4  2.3
Loco-regional recurrence
Without (n Z 27) 3.7  2.3 0.185
With (n Z 33) 4.6  2.5
Histology of OSCC
Well-differentiated (n Z 51) 4.3  2.4 0.236
Moderately-differentiated
(n Z 9)
3.3  2.7
608 H.-H. Ko et al.clinicopathological parameters of 60 OSCC patients is
shown in Table 2. We found that the mean VEGF mRNA DCT
value was significantly lower in OSCC patients with a larger
tumor size (p Z 0.040), positive lymph node metastasis
(pZ 0.023), and more advanced clinical stages (pZ 0.008)
(Table 2). No significant correlation was found between theTable 3 Univariate and multivariate overall survival analyses o
eters in 60 patients with oral squamous cell carcinoma using Cox
Factor
Univariate
T status (T1 þ T2 vs. T3 þ T4)
N status (N0 vs. N1 þ N2 þ N3)
Clinical stage (Stage 1 þ 2 vs. stage 3 þ 4)
VEGF mRNA DCT value (4.2 vs. < 4.2)
Multivariate
N status (N0 vs. N1 þ N2 þ N3)
VEGF mRNA DCT value (4.2 vs. < 4.2)mean VEGF mRNA DCT value and patients’ age, sex, cancer
location, loco-regional recurrence, or histology of OSCC.
The VEGF mRNA DCT value was also not associated with the
areca quid chewing, cigarette smoking, or alcohol drinking
habit (data not shown).
Survival analysis
In this study, the median follow-up duration was 47 months
for 60 OSCC patients. Univariate analysis performed using
Cox proportional hazard regression model identified larger
tumor size (p Z 0.026), positive lymph node metastasis
(p Z 0.009), more advanced clinical stages (p Z 0.022),
and VEGF mRNA DCT value < 4.2 (p Z 0.018, the median
VEGF mRNA DCT value was 3.9) as correlating with poorer
survival of OSCC patients. Multivariate analyses with Cox
proportional hazard regression model further identified
positive lymph node metastasis (p Z 0.029) and VEGF
mRNA DCT value < 4.2 (p Z 0.026) as two independent
unfavorable prognosis factors (Table 3). In this study, the
median overall survival was 37 months for the patients with
VEGF mRNA DCT value <4.2 and 41 months for the patients
with VEGF mRNA DCT value 4.2 [HR (95% CI),
3.275(1.078e11.167)]. The KaplaneMeier curve showed
that OSCC patients with a VEGF mRNA DCT value <4.2 had a
significantly poorer cumulative overall survival than those
with a VEGF mRNA DCT value 4.2 (p Z 0.0427, log-rank
test, Figure 2).
Discussion
This study measured the VEGF mRNA level in 60 OSCC and
38 NOM samples. We found a significantly lower mean VEGF
mRNA DCT value in OSCC samples than in NOM samples,
indicating an increased VEGF mRNA expression in OSCC
samples than in NOM samples. Similarly, Berse et al31
discovered a greater VEGF mRNA expression in renal cell
carcinomas and colonic adenocarcinomas than in normal
kidney and normal bowel mucosa tissues, respectively.
Brown et al32 also reported a significantly higher VEGF
mRNA expression in gastrointestinal adenocarcinoma tis-
sues than in normal epithelium. In addition, Guidi et al33
demonstrated an elevated VEGF mRNA and protein
expression in endometrial carcinomas than in normal
endometrial tissues. The significantly higher expression of
VEGF mRNA in cancerous tissues than in correspondingf the VEGF mRNA expression and clinicopathological param-
proportional hazard regression model.
Hazard ratio (95% CI) p
3.473 (1.085e11.119) 0.026
4.317 (1.432e11.947) 0.009
3.374 (1.759e8.131) 0.022
3.275 (1.078e11.167) 0.018
5.890 (1.202e28.865) 0.029
2.285 (1.556e14.234) 0.026
Figure 2 Kaplan-Meier survival curve showing a significant
relation between cancer tissue vascular endothelial growth
factor (VEGF) mRNA levels in 60 patients with oral squamous
cell carcinoma (OSCC) and the overall survival of these 60 OSCC
patients. The duration of overall survival was measured from
the beginning of surgery to the time of death (complete) or the
last follow-up (censored). The cumulative overall survival for
OSCC patients with VEGF mRNA DCT < 4.2 was significantly
poorer than that for OSCC patients with VEGF mRNA DCT  4.2
(p Z 0.0427, log-rank test).
VEGF mRNA in oral cancer tissues 609normal tissues suggests that VEGF mRNA level can be used
as a biomarker for oral, renal cell, gastrointestinal, and
endometrial cancers. Indeed, upregulation of VEGF mRNA
or protein has been detected in a variety of human
cancers.10e29,34
VEGF can promote angiogenesis which is a pivotal factor
for tumor growth and metastasis.8,9 This study demon-
strated a significant association of upregulation of VEGF
mRNA in OSCC specimens with larger tumor size and posi-
tive lymph node metastasis. Our previous study also found a
positive correlation between higher VEGF protein expres-
sion in OSCC tissues and positive regional lymph node
metastasis.26 A positive correlation between over-
expression of VEGF protein or mRNA in cancer tissues and
lymph node metastasis has also been reported in head and
neck SCCs23,29 as well as oral and pharyngeal SCCs.28
VEGF can promote tumor growth because it can increase
neovascularization. We further explained why VEGF can
augment lymph node metastasis as follows. Firstly, VEGF is
a mitogen for vascular endothelial cells and helps the
migration and organization of vascular endothelial cells for
neovascularization and tumor micrometastasis.8,9 VEGF-A
and -B are mainly angiogenic factors while VEGF-C is a
lymphangiogenic factor.35,36 VEGF can inhibit endothelial
cell apoptosis, increase endothelial cell proliferation and
migration, enhance vascular permeability, and thus pro-
mote metastasis.5,6 Secondly, VEGF augments the expres-
sion of matrix metalloproteinase 9 (MMP9) which facilitates
the cancer cell invasion and metastasis.8,37 Additionally,
VEGF-induced Akt phosphorylation leads to the increased
motility of human OSCC cell line.37,38 Thirdly, VEGF also
mediates tumor evasion of normal immune surveillance by
inhibiting the development of dendritic cells, and in turnsuppresses the antigen recognition and antitumor immune
defense.37,38 Therefore, VEGF may promote lymph node
metastases through multiple mechanisms such as an in-
crease in tumor angiogenesis and lymphangiogenesis, an
increase in tumor cell survival, motility, migration and in-
vasion, an elevated expression of MMP9, and an inhibition
of the immune surveillance by dendritic cells.
This study displayed a significant association of greater
VEGF mRNA expression in OSCCs with a larger tumor size
and positive lymph node metastasis. Because higher T and N
statuses always indicate an advanced clinical stage, OSCC
patients with a higher expression of VEGF mRNA are prone
to have more advanced clinical stages. Actually, higher
VEGF protein expression has been found to be related to
the more advanced clinical stages of colon and gastric
carcinomas.11,15
The present study demonstrated a significant correlation
between higher VEGF mRNA expression in OSCCs and poorer
overall survival in OSCC patients. In addition, VEGF mRNA
DCT value <4.2 was identified as an independent unfavor-
able prognosis factor using multivariate regression ana-
lyses. A significant association of elevated VEGF m-RNA or
protein expression with disease-free or overall survival has
also been discovered in head and neck SCC patients
including OSCC patients.22e27 Previous studies also showed
a significant association of higher levels of VEGF mRNA or
protein with a shorter survival in patients with colorectal,10
gastric,14 pancreatic,17 and breast18e20 carcinomas. The
above findings indicate that VEGF protein or mRNA level
may be an important prognostic factor for patients with
certain types of human carcinomas including OSCC.
Immunohistochemistry and quantitative RT-PCT are two
excellent techniques to confirm a histopathological diag-
nosis of a tumor or to find a biomarker for prediction of
cancer progression and prognosis.39e49 This study showed
an intimate and significant relationship between the
elevated VEGF mRNA level and larger tumor size, higher N
status, and more advanced clinical stage of OSCCs. More-
over, OSCC patients with a higher VEGF mRNA expression
had a poorer cumulative overall survival than those with
lower VEGF mRNA levels. VEGF mRNA DCT value <4.2 was
also identified as an independent unfavorable prognosis
factor for OSCCs using multivariate regression analyses.
However, the sample size of this study is relatively small,
thus a large-scale study with an adequate number of OSCCs
is needed to confirm the results of the present study. We
conclude that the VEGF mRNA level may be a biomarker for
prediction of the progression and prognosis of OSCCs in
Taiwan.
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